Read + Share
Karn T, Meissner T, Weber K, Solbach C, et al. A small hypoxia signature predicted pCR response to bevacizumab in the
neoadjuvant GeparQuinto breast cancer trial. Clin Cancer Res 2020 Jan 13. pii: 1078-0432.CCR-19-1954.
PMID: 31932495
|
 |
|
Karn T, Meissner T, Weber K, Solbach C, et al. A small hypoxia signature predicted pCR response to bevacizumab in the
neoadjuvant GeparQuinto breast cancer trial. Clin Cancer Res 2020 Jan 13. pii: 1078-0432.CCR-19-1954.
PMID: 31932495
|
|
|
|